Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 15, 2026

Applied Materials Q2 Earnings Beat Estimates, Revenues Increase Y/Y

View original at finance.yahoo.com
Applied Materials Q2 Earnings Beat Estimates, Revenues Increase Y/Y Applied Materials AMAT reported second-quarter fiscal 2026 non-GAAP earnings of $2.86 per share, which beat the Zacks Consensus Estimate by 6.5%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EPIC platform is designed to shorten commercialization cycles from research to full-scale manufacturing

    60% confidence
  • Applied Materials has more than 35,000 users across its global workforce adopting AI internally

    60% confidence
  • AI demand is expanding beyond training and inference into agentic applications, which are more CPU-intensive and can raise demand for DRAM and NAND

    60% confidence
  • EPIC collaboration model will improve R&D productivity, increase multi-node visibility for investment decisions, and accelerate design wins for tools and services

    60% confidence
  • Quarter strength driven by the rapid global build-out of AI computing infrastructure and Applied Materials' leadership in leading-edge foundry-logic, DRAM and advanced packaging

    60% confidence
  • Largest customers are providing rolling eight-quarter forecasts, supporting planning for capacity and service resources

    60% confidence
  • The EPIC Center in Silicon Valley remains on track to begin operations in the fall

    60% confidence

Data points we hold from this source

Applied Materials, Inc. · eps2.86 USD
Applied Materials, Inc. · average earnings surprise7.1 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com